Safety and efficacy of two doses of belzutifan in patients (pts) with advanced RCC: Results of the randomized phase II LITESPARK-013 study

被引：5
|
作者：
Agarwal, N. [1 ]
Brugarolas, J. [2 ]
Ghatalia, P. [3 ]
George, S. [4 ]
Haanen, J. B. A. G. [5 ]
Gurney, H. P. [6 ]
Ravilla, R. [7 ]
Van der Veldt, A. A. M. [8 ]
Beuselinck, B. [9 ]
Pokataev, I. [10 ]
Suelmann, B. B. [11 ]
Tuthill, M. [12 ]
Vaena, D. [13 ]
Zagouri, F. [14 ]
Wu, J. [15 ]
Liu, Y. [15 ]
Perini, R. [15 ]
Merchan, J. R. [16 ]
Atkins, M. B. [17 ]
机构：
[1] Huntsman Canc Inst, Oncol Internal Med Dept, Salt Lake City, UT USA
[2] Univ Texas Southwestern Med Ctr, Internal Med Hematol Oncol, Dallas, TX USA
[3] Fox Chase Canc Ctr, Hematol Oncol, Philadelphia, PA USA
[4] Roswell Pk Canc Inst, Oncol, Buffalo, NY USA
[5] Netherlands Canc Inst, Oncol, Amsterdam, Netherlands
[6] Macquarie Univ, Oncol, Sydney, NSW, Australia
[7] Albany Canc Ctr, Oncol, New York Oncol Hematol, Albany, NY USA
[8] Erasmus MC, Oncol, Rotterdam, Netherlands
[9] UZ Leuven, Oncol, Leuven, Belgium
[10] City Clin Oncol Hosp 1, Oncol, Moscow, Russia
[11] Univ Med Ctr Utrecht, Med Oncol, Utrecht, Netherlands
[12] Oxford Univ Hosp NHS Fdn Trust, Oncol & Hematol, London, England
[13] West Canc Ctr & Res Inst, Oncol, Germantown, TN USA
[14] Alexandra Reg Gen Hosp, Oncol, Athens, Greece
[15] Merck & Co Inc, Oncol, Rahway, NJ USA
[16] Univ Miami Hosp & Clin, Oncol, Sylvester Canc Ctr, Canc Res Serv, Miami, FL USA
[17] Georgetown Univ, Oncol, Med Ctr, Washington, DC USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1111
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1881O
引用
收藏
页码：S1011 / S1011
页数：1
相关论文
共 50 条
  • [41] A phase II study of tinostamustine in patients (pts) with advanced solid tumours
    Tinker, Anna
    Strauss, James Fredric
    Schneider, Reva
    Chugh, Rashmi
    Curigliano, Giuseppe
    Di Nicola, Massimo A.
    Oaknin, Ana
    Janik, Tomas
    Hilgier, Kasia
    Manamley, Nick
    Kummar, Shivaani
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] Efficacy and safety of sorafenib in patients with advanced clear-cell renal cell carcinoma (RCC) with diabetes: Results from the phase III TARGET study
    Oudard, S.
    Eisen, T.
    Szczylik, C.
    Siebels, M.
    Negrier, S.
    Chevreau, C.
    Cihon, F.
    Bukowski, R. M.
    Escudier, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [43] A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results
    Segal, Neil Howard
    Girda, Eugenia
    Sohal, Davendra
    Lakhani, Nehal J.
    Olszanski, Anthony J.
    Fong, Lawrence
    Kinnaman, Michael David
    Han, Hyunsil
    Skokos, Dimitris
    Casey, Kerry A.
    Wang, JuAn
    Wang, Bei
    Hao, Yi
    Li, Siyu
    Ganguly, Samit
    Lowy, Israel
    Seebach, Frank A.
    Mathias, Melissa Divya
    Johnson, Melissa Lynne
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [44] A phase (Ph) II study of the efficacy and safety of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Tanwandee, Tawesak
    Sukeepaisarnjaroen, Wattana
    Chan, Stephen Lam
    Choo, SuPin
    Han, Guohong
    Sriuranpong, Virote
    Pan, Hongming
    Yau, Thomas Cheung
    Ren, Zhenggang
    Xu, Jian-Ming
    Peng, Bin
    Saji, Takami
    Sun, Yongjian
    Huang, Alan
    Manenti, Luigi
    Qin, Shukui
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [45] A Phase I/II study to assess the safety and efficacy of pazopanib (paz) and pembrolizumab (pembro) in patients (pts) with advanced renal cell carcinoma (aRCC)
    McDermott, D. F.
    Infante, J. R.
    Chowdhury, S.
    Voss, M. H.
    Motzer, R. J.
    Perini, R. F.
    Morosky, A.
    Zheng, F. F.
    White, B. C.
    Wang, Q.
    Jewell, R. C.
    Rini, B. I.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S519 - S520
  • [46] A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC).
    Chowdhury, Simon
    McDermott, David F.
    Voss, Martin Henner
    Hawkins, Robert E.
    Aimone, Paola
    Voi, Maurizio
    Isabelle, Naeije
    Wu, Vi
    Infante, Jeffrey R.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [47] University of Chicago Consortium phase II study of ispinesib (SB-715992) in patients (pts) with advanced renal cell carcinoma (RCC)
    Beekman, K. W.
    Dunn, R.
    Colevas, D.
    Davis, N.
    Clark, J.
    Agamah, E.
    Thomas, S.
    Nichols, K.
    Redman, B.
    Stadler, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [48] Results of a randomized phase II study investigating multipeptide vaccination with IMA901 in advanced renal cell carcinoma (RCC)
    Reinhardt, C.
    Zdrojowy, R.
    Szczylik, C.
    Ciulenau, T.
    Brugger, W.
    Oberneder, R.
    Kirner, A.
    Walter, S.
    Singh, H.
    Stenzl, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [49] A randomized, open label, multicenter phase 2 study to evaluate the efficacy of sorafenib in patients (pts) with advanced Renal Cell Carcinoma (RCC) after a radical resection of the metastases.
    Verzoni, Elena
    Grassi, Paolo
    Montone, Rosanna
    Maggi, Claudia
    Cognetti, Francesco
    Milella, Michele
    Bearz, Alessandra
    Ortega, Cinzia
    Morelli, Franco
    Chiuri, Vincenzo Emanuele
    Necchi, Andrea
    De Braud, Filippo G.
    Procopio, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [50] METEOR: results from the randomized phase 3 trial of cabozantinib versus everolimus in pts with advanced renal cell carcinoma (RCC)
    Powles, Thomas
    Escudier, Bernard
    Mainwaring, Paul N.
    Rini, Brian I.
    Donskov, Frede
    Hammers, Hans J.
    Hutson, Thomas E.
    Roth, Bruce
    Peltola, Katriina
    Lee, Jae Lyun
    Heng, Daniel Y. C.
    Schmidinger, Manuela
    Borgman, Anne
    Hessel, Colin
    Scheffold, Christian
    Schwab, Gisela
    Tannir, Nizar M.
    Motzer, Robert J.
    Choueiri, Toni K.
    BJU INTERNATIONAL, 2015, 116 : 19 - 19
12345